Knowledge graph · Cancer
Myeloid Leukemia, Philadelphia-Negative
hematologic malignancy
- Identifier
- CI-CAN-00003384
- Edges
- 32
- Neighbours
- 14 drugs10 trials
- Drawn
- 24 of 24 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Myeloid Leukemia, Philadelphia-Negative approved for …APPROVED_FORderived9 of 9 | ||||||||
| ← approved for | Nilotinibsmall molecule FDA (US) · approved · 2026-05-29 · Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatini… | — | approved | Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive | 1 | Regulatory | openfda | graph → |
| approved for | ||||||||